162 related articles for article (PubMed ID: 9559843)
1. Role of the transition zone for elevating serum prostate-specific antigen in benign prostatic hyperplasia.
Sakamoto W; Iwata H; Kamikawa S; Tsurusaki K; Sugimoto T; Nakatani T; Sugimura K; Yamamoto K; Kishimoto T
Int J Urol; 1998 Mar; 5(2):163-6. PubMed ID: 9559843
[TBL] [Abstract][Full Text] [Related]
2. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia.
Mikolajczyk SD; Millar LS; Wang TJ; Rittenhouse HG; Wolfert RL; Marks LS; Song W; Wheeler TM; Slawin KM
Urology; 2000 Jan; 55(1):41-5. PubMed ID: 10654892
[TBL] [Abstract][Full Text] [Related]
3. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
[TBL] [Abstract][Full Text] [Related]
4. Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
Abdel-Khalek M; Sheir KZ; El-Baz M; Ibrahiem el-H
Scand J Urol Nephrol; 2005; 39(1):49-55. PubMed ID: 15764271
[TBL] [Abstract][Full Text] [Related]
5. Enhanced expression of prostate-specific antigen in the transition zone of the prostate. A characterization following prostatectomy for benign hyperplasia.
Recker F; Kwiatkowski MK; Pettersson K; Piironen T; Lümmen G; Huber A; Tscholl R
Eur Urol; 1998; 33(6):549-55. PubMed ID: 9743696
[TBL] [Abstract][Full Text] [Related]
6. Can the intraprostatic concentration of epidermal growth factor influence the variance of serum prostate specific antigen levels in patients with benign prostatic hyperplasia?
Di Silverio F; Sciarra A; Monti S; Casale P; Seccareccia F
J Urol; 1999 Jan; 161(1):128-32. PubMed ID: 10037384
[TBL] [Abstract][Full Text] [Related]
7. Between-subject variations of transition zone epithelial volume and serum PSA levels in men with benign prostatic hyperplasia.
Oreste M; Giuseppe PG; Gianna P; Adriano A; Stefano N; Mauro B; Carlo V
World J Urol; 2010 Jun; 28(3):379-83. PubMed ID: 19690867
[TBL] [Abstract][Full Text] [Related]
8. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
[TBL] [Abstract][Full Text] [Related]
9. Relationship between prostatic epithelial volume and serum prostate-specific antigen levels.
Lepor H; Wang B; Shapiro E
Urology; 1994 Aug; 44(2):199-205. PubMed ID: 7519380
[TBL] [Abstract][Full Text] [Related]
10. Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate.
Hammerer PG; McNeal JE; Stamey TA
J Urol; 1995 Jan; 153(1):111-4. PubMed ID: 7526003
[TBL] [Abstract][Full Text] [Related]
11. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
Stephan C; Lein M; Jung K; Schnorr D; Loening SA
Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
[TBL] [Abstract][Full Text] [Related]
12. Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction.
Djavan B; Remzi M; Zlotta AR; Seitz C; Wolfram R; Hruby S; Bursa B; Schulman CC; Marberger M
Tech Urol; 1999 Jun; 5(2):71-6. PubMed ID: 10458658
[TBL] [Abstract][Full Text] [Related]
13. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
Steuber T; Niemela P; Haese A; Pettersson K; Erbersdobler A; Felix Chun KH; Graefen M; Kattan MW; Huland H; Lilja H
Prostate; 2005 Apr; 63(1):13-8. PubMed ID: 15378521
[TBL] [Abstract][Full Text] [Related]
14. Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?
Djavan B; Zlotta AR; Remzi M; Ghawidel K; Bursa B; Hruby S; Wolfram R; Schulman CC; Marberger M
Urology; 1999 Nov; 54(5):846-52. PubMed ID: 10565745
[TBL] [Abstract][Full Text] [Related]
15. Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels.
Horninger W; Reissigl A; Klocker H; Rogatsch H; Fink K; Strasser H; Bartsch G
Prostate; 1998 Nov; 37(3):133-7; discussion 138-9. PubMed ID: 9792130
[TBL] [Abstract][Full Text] [Related]
16. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
[TBL] [Abstract][Full Text] [Related]
17. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
18. Changes in serum prostate-specific antigen following prostatectomy in patients with benign prostate hyperplasia.
Furuya Y; Akakura K; Tobe T; Ichikawa T; Igarashi T; Ito H
Int J Urol; 2000 Dec; 7(12):447-51. PubMed ID: 11168683
[TBL] [Abstract][Full Text] [Related]
19. Percent of free serum prostate-specific antigen and histological findings in patients undergoing open prostatectomy for benign prostatic hyperplasia.
Scattoni V; Raber M; Montorsi F; Da Pozzo L; Brausi M; Calori G; Freschi M; Rigatti P
Eur Urol; 1999 Dec; 36(6):621-30. PubMed ID: 10559617
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen, prostate volume and transition zone volume in Japanese patients with histologically proven benign prostatic hyperplasia.
Furuya Y; Ohta S; Sato N; Kotake T; Masai M
Int Urol Nephrol; 2001; 33(4):645-8. PubMed ID: 12452619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
